These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29859754)

  • 21. Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers.
    Lin AJ; Rao YJ; Chin RI; Campian J; Mullen D; Thotala D; Daly M; Gay H; Oppelt P; Hallahan D; Adkins D; Thorstad W
    Oral Oncol; 2018 Nov; 86():1-7. PubMed ID: 30409288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy.
    Stam B; van der Bijl E; van Diessen J; Rossi MMG; Tijhuis A; Belderbos JSA; Damen E; Sonke JJ
    Radiother Oncol; 2017 Oct; 125(1):62-65. PubMed ID: 28939179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy.
    Akthar AS; Koshy M; Ferguson MK; Murgu S; Hogarth DK; Golden DW; Connell PP; Davies EM; Kowalski E; Malik R
    Clin Lung Cancer; 2018 Mar; 19(2):e227-e233. PubMed ID: 28939097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
    Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
    Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.
    Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C
    J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer.
    Zhao L; Ji W; Zhang L; Ou G; Feng Q; Zhou Z; Lei M; Yang W; Wang L
    J Thorac Oncol; 2010 Apr; 5(4):521-5. PubMed ID: 20130485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.
    Tang C; Liao Z; Gomez D; Levy L; Zhuang Y; Gebremichael RA; Hong DS; Komaki R; Welsh JW
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1084-1091. PubMed ID: 25035212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
    Derman BA; Macklis JN; Azeem MS; Sayidine S; Basu S; Batus M; Esmail F; Borgia JA; Bonomi P; Fidler MJ
    BMC Cancer; 2017 Feb; 17(1):141. PubMed ID: 28209123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non-small cell lung cancer.
    Han JE; Hasan S; Choi JI; Press RH; Simone CB
    Cancer Med; 2021 Sep; 10(17):5794-5808. PubMed ID: 34350713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer.
    Sun Y; Hawkins PG; Bi N; Dess RT; Tewari M; Hearn JWD; Hayman JA; Kalemkerian GP; Lawrence TS; Ten Haken RK; Matuszak MM; Kong FM; Jolly S; Schipper MJ
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):107-114. PubMed ID: 29051037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
    Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing.
    Huang HT
    Radiother Oncol; 2024 Nov; 200():110477. PubMed ID: 39153508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.
    Wada K; Kishi N; Kanayama N; Hirata T; Morimoto M; Konishi K; Imamura F; Teshima T; Ogawa K
    Anticancer Res; 2018 Oct; 38(10):5951-5958. PubMed ID: 30275224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
    PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression?
    Thor M; Montovano M; Hotca A; Luo L; Jackson A; Wu AJ; Deasy JO; Rimner A
    Radiother Oncol; 2020 Feb; 143():51-57. PubMed ID: 31615633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.